Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases
AssigneeImmunityBio, Inc.
InventorsHing C. Wong, Xiaoyun Zhu, Pallavi Chaturvedi, Varghese George, Niraj Shrestha, Michael Dee
Life of this patent
Estimating the term…
Abstract
Provided herein are multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases.
Claims19
1-61. (canceled)
A method of reducing inflammation in a liver of a subject having type 2 diabetes, wherein the method comprises administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide comprising:
- (a) a first chimeric polypeptide comprising:
- (i) a first target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO:4;
- (ii) soluble tissue factor domain comprising a sequence that is at least 90% identical to SEQ ID NO:1;
- and
- (iii) a first domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:18;
- (b) a second chimeric polypeptide comprising:
- (i) a second domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:16;
- and
- (ii) a second target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO:4,
- wherein:
- the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains;
- and
- the first target-binding domain binds specifically to a ligand of TGF-β receptor II (TGF-βRII) and the second target-binding domain binds specifically to a ligand of TGF-βRII.
A method of decreasing hepatocytic senescence in a liver of a subject having type 2 diabetes, wherein the method comprises administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide comprising:
- (a) a first chimeric polypeptide comprising:
- (i) a first target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO:4;
- (ii) soluble tissue factor domain comprising a sequence that is at least 90% identical to SEQ ID NO:1;
- and
- (iii) a first domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:18;
- (b) a second chimeric polypeptide comprising:
- (i) a second domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:16;
- and
- (ii) a second target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO:4,
- wherein:
- the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains;
- and
- the first target-binding domain binds specifically to a ligand of TGF-β receptor II (TGF-βRII) and the second target-binding domain binds specifically to a ligand of TGF-βRII.
A method of rebalancing metabolic function in a liver of a subject having type 2 diabetes, wherein the method comprises administering to the subject a therapeutically effective amount of a multi-chain chimeric polypeptide comprising:
- (a) a first chimeric polypeptide comprising:
- (i) a first target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO:4;
- (ii) soluble tissue factor domain comprising a sequence that is at least 90% identical to SEQ ID NO:1;
- and
- (iii) a first domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:18;
- (b) a second chimeric polypeptide comprising:
- (i) a second domain of a pair of affinity domains comprising a sequence that is at least 90% identical to SEQ ID NO:16;
- and
- (ii) a second target-binding domain comprising a sequence that is at least 90% identical to SEQ ID NO:4,
- wherein:
- the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains;
- and
- the first target-binding domain binds specifically to a ligand of TGF-β receptor II (TGF-βRII) and the second target-binding domain binds specifically to a ligand of TGF-βRII.
Dependencies are inferred from the claim text.